Evidence map›Paper›PMID 26405233›Full record

Trial reportEuropean heart journal2016

A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial†.

Fizzah Choudry, Stephen Hamshere, Natalie Saunders, Jessry Veerapen, Katrine Bavnbek, Charles Knight, Denis Pellerin, Didier Locca, Mark Westwood, Roby Rakhit and 7 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 8 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 8 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Stem cell therapy for dilated cardiomyopathy.The Cochrane database of systematic reviews · 2021
    Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Stem Cell Therapy in Ischemic Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

Fizzah ChoudryDepartment of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
Stephen HamshereDepartment of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
Natalie SaundersStem Cell Laboratory, Barts Health NHS Trust and Blizard Institute, Queen Mary University of London, London, UK.
Jessry VeerapenDepartment of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
Katrine BavnbekInstitute of Cardiovascular Science, University College London, The Heart Hospital, UCLH, 16-18 Westmoreland Street, London W1G 8PH, UK.
Charles KnightDepartment of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
Denis PellerinInstitute of Cardiovascular Science, University College London, The Heart Hospital, UCLH, 16-18 Westmoreland Street, London W1G 8PH, UK.
Didier LoccaService de Cardiologie et Département de Médecine Interne, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Mark WestwoodDepartment of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
Roby RakhitDepartment of Cardiology, The Royal Free Hospital, Royal Free London Foundation Trust, London, UK.
Tom CrakeInstitute of Cardiovascular Science, University College London, The Heart Hospital, UCLH, 16-18 Westmoreland Street, London W1G 8PH, UK.
Jens KastrupDepartment of Cardiology, Rigshopitale, University of Copenhagen, Copenhagen, Denmark.
Mahesh ParmarCancer Division, Medical Research Council Clinical Trials Unit, London, UK.
Samir AgrawalStem Cell Laboratory, Barts Health NHS Trust and Blizard Institute, Queen Mary University of London, London, UK.
Daniel JonesDepartment of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.
John MartinBritish Heart Foundation Laboratories, Department of Medicine, University College London, London WC1E 6JJ, UK.
Anthony MathurDepartment of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK Barts Health NIHR Cardiovascular Biomedical Research Unit, Barts Health NHS Trust, London EC1A 7BE, UK a.mathur@qmul.ac.uk.
St Bartholomew's Hospital · GBUniversity College London · GBBarts Health NHS Trust · GBQueen Mary University of London · GBMedical Research Council · GBRoyal Free London NHS Foundation Trust · GBUniversity College Hospital at Westmoreland Street · GBUniversity Hospital of Lausanne · CHUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsClinical trials suggest that intracoronary delivery of autologous bone marrow-derived cells (BMCs) 1-7 days post-acute myocardial infarction (AMI) may improve left ventricular (LV) function. Earlier time points have not been evaluated. We sought to determine the effect of intracoronary autologous BMC on LV function when delivered within 24 h of successful reperfusion therapy. METHODS AND

resultsA multi-centre phase II randomized, double-blind, and placebo-controlled trial. One hundred patients with anterior AMI and significant regional wall motion abnormality were randomized to receive either intracoronary infusion of BMC or placebo (1:1) within 24 h of successful primary percutaneous intervention (PPCI). The primary endpoint was the change in left ventricular ejection fraction (LVEF) between baseline and 1 year as determined by advanced cardiac imaging. At 1 year, although LVEF increased compared with baseline in both groups, the between-group difference favouring BMC was small (2.2%; 95% confidence interval, CI: -0.5 to 5.0; P = 0.10). However, there was a significantly greater myocardial salvage index in the BMC-treated group compared with placebo (0.1%; 95% CI: 0.0-0.20; P = 0.048). Major adverse events were rare in both treatment groups.

conclusionThe early infusion of intracoronary BMC following PPCI for patients with AMI and regional wall motion abnormality leads to a small non-significant improvement in LVEF when compared with placebo; however, it may play an important role in infarct remodelling and myocardial salvage.

Indexed as

Anterior Wall Myocardial InfarctionBone Marrow TransplantationComputed Tomography AngiographyDouble-Blind MethodFemaleHumansMagnetic Resonance AngiographyMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPercutaneous Coronary InterventionQuality of LifeSalvage TherapyStroke VolumeTransplantation, AutologousNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Acute myocardial infarctionCardiac magnetic resonance imagingPrimary percutaneous coronary interventionStem cell therapy

Identifiers

PMID26405233
PMCPMC4712349
OpenAlexW2196154435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.